Lv1
50 积分 2024-11-01 加入
Tyrosine Kinase Inhibitor (TKI) Maintenance Improves Remission Durability in Philadelphia-Chromosome Acute Lymphoblastic Leukemia (Ph+ ALL) Following Brexucabtagene Autoleucel (Brexu-cel)
1天前
求助中
Efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy or CAR-T cells for relapsed/refractory acute lymphoblastic leukemia: A multicenter phase ii trial
1天前
已关闭
Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients
1天前
已完结
Tyrosine Kinase Inhibitor (TKI) Maintenance Improves Remission Durability in Philadelphia-Chromosome Acute Lymphoblastic Leukemia (Ph+ ALL) Following Brexucabtagene Autoleucel (Brexu-cel)
5天前
已关闭
Advances and Controversies in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Navigating First-Line Therapies
8天前
已完结
Second‐line chimeric antigen receptor T‐cell therapy versus standard of care in relapsed or refractory large B‐cell lymphoma: A systematic review and meta‐analysis
16天前
已完结
[Expert consensus on the management practice of CD19 CAR-T cell therapy for B-cell lymphoma in China (2025 edition)]
1个月前
已关闭
Axicabtagene Ciloleucel in Large B-Cell Lymphoma
2个月前
已完结
Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era
2个月前
已完结
Chimeric antigen receptor T‐cell therapy combined with autologous stem cell transplantation improved progression‐free survival of relapsed or refractory diffuse large B‐cell lymphoma patients: A single‐center, retrospective, cohort study
2个月前
已完结
皖公网安备34019202002308
